Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373295 · ClinicalTrials.gov registry record · Phase 2
Effect of Baclofen on Marijuana Withdrawal and Relapse
A Phase 2 study of Marijuana Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00373295: Completed Phase 2 study of Marijuana Dependence, sponsored by New York State Psychiatric Institute.
NCT00373295 is a Phase 2 study of Marijuana Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 13 participants, below the 90-participant average among 6 other Marijuana Dependence trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00373295, a Phase 2 study of Marijuana Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
Primary Outcome
This is a measure of marijuana self-administration and relapse since each initial puff costs $7 and is a burden to overcome just to smoke. Over each 3 day period, the puffs chosen by each participant is averaged for a single value.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baclofen
- DRUG Marijuana
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00373295 record still lists
NCT00373295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 90-participant average among 6 other Marijuana Dependence trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Marijuana Dependence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00373295 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00373295 about?
NCT00373295 is a clinical study titled "Effect of Baclofen on Marijuana Withdrawal and Relapse". The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
What is the current status of trial NCT00373295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-05. Estimated completion is 2010-01.
What conditions does trial NCT00373295 study?
This clinical trial studies the following conditions: Marijuana Dependence.
What interventions are being tested in trial NCT00373295?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT00373295?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373295 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vilazodone Treatment for Marijuana Dependence
COMPLETED · Phase 2
-
Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
COMPLETED · Phase 2
-
Effect of Oxytocin on Craving and Therapy Response
COMPLETED · NA
-
Buspirone Treatment for Marijuana Dependence
COMPLETED · Phase 4
-
Marijuana Treatment Project 4
COMPLETED · NA
-
Effect of Oxytocin on Stress in Marijuana Users
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia